Table 1.

Baseline characteristics of 48 patients with intensive care unit (ICU)-acquired bacteraemias whether they received or not an aminoglycoside as combination therapy

	Aminoglycoside not received		Aminoglycoside received		p-value
	n = 30		n = 18
	n	%	n	%
Female sex	14	46	7	38	0.59
Comorbidities
Cardiac disease	8	26	4	32	1
Diabetes mellitus	7	23	8	44	0.13
COPD	11	37	11	61	0.1
Chronic liver failure	5	16	0	0	0.14
Chronic alcoholism	10	33	4	22	0.52
Chronic renal failure	2	7	1	6	1
Non-haematologic malignancy	3	10	1	6	1
Haematologic malignancy	3	10	0	0	0.28
Immunosuppression	5	16	0	0	0.14
Organ failure
Cardiac failure	7	23	3	16	0.72
Renal failure	7	23	1	6	0.23
Respiratory failure	29	96	17	94	1
Coagulation failure	2	7	0	0	0.52
Hepatic failure	3	10	0	0	0.28
Neurologic failure	2	7	2	11	0.62
Severity of illness	Mean ± SD		Mean ± SD		p-value
SAPS II	49.5 ± 14.8		48.7 ± 18.6		0.71
SOFA score	6.1 ± 3.2		5.2 ± 1.8		0.57
Clinical and biological presentation
Age (years)	62 ± 13		68 ± 8		0.12
Temperature (°C)	38.3 ± 1.1		38.6 ± 1.01		0.94
Leukocyte count (/mm3)	15,489 ± 12,352		17,828 ± 10,439		0.24
Platelet count (1,000/mm3)	255 ± 173		273 ± 143		0.50
pH	7.40 ± 0.07		7.39 ± 0.07		0.48
Lactate (meq/l)	1.63 ± 1.00		1.25 ± 0.41		0.60
Serum urea (g/l)	0.66 ± 0.38		0.59 ± 0.35		0.52
Creatinine (mg/l)	11 ± 5		12 ± 7		0.54
PaO2/FiO2	290 ± 108		266 ± 84		0.75
Bilirubin (mg/l)	66 ± 137		9 ± 8		0.03
Prothrombin time (%)	74 ± 17		84 ± 10		0.20
CRP (mg/l)	121 ± 78		107 ± 90		0.55
Treatment
Vasopressive drugs	6	20	4	22	0.85
Mechanical ventilation	29	97	17	94	0.71
Renal replacement therapy	6	20	0	0	0.07